Cargando…
The MOC31PE immunotoxin reduces cell migration and induces gene expression and cell death in ovarian cancer cells
BACKGROUND: The standard treatment of ovarian cancer with chemotherapy often leads to drug resistance and relapse of the disease, and the need for development of novel therapy alternatives is obvious. The MOC31PE immunotoxin binds to the cell surface antigen EpCAM, which is expressed by the majority...
Autores principales: | Wiiger, Merete Thune, Bideli, Hemaseh, Fodstad, Øystein, Flatmark, Kjersti, Andersson, Yvonne |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3931919/ https://www.ncbi.nlm.nih.gov/pubmed/24528603 http://dx.doi.org/10.1186/1757-2215-7-23 |
Ejemplares similares
-
MOC31PE immunotoxin – targeting peritoneal metastasis from epithelial ovarian cancer
por: Andersson, Yvonne, et al.
Publicado: (2017) -
Increased Local Inflammatory Response to MOC31PE Immunotoxin After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
por: Thorgersen, Ebbe Billmann, et al.
Publicado: (2021) -
Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin
por: Andersson, Y, et al.
Publicado: (2015) -
Synergistic Anticancer Effects of the 9.2.27PE Immunotoxin and ABT-737 in Melanoma
por: Risberg, Karianne, et al.
Publicado: (2011) -
A novel human recombinant single-chain antibody targeting CD166/ALCAM inhibits cancer cell invasion in vitro and in vivo tumour growth
por: Wiiger, Merete Thune, et al.
Publicado: (2010)